Ronnen Armon - 18 Mar 2026 Form 3 Insider Report for Cellebrite DI Ltd. (CLBT)

Role
Chief Products & Technologies Officer
Signature
/s/ Ronnen Armon
Issuer symbol
CLBT
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 08:23:14 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Armon Ronnen Chief Products & Technologies Officer 94 SHLOMO SHMELZER ROAD, PETAH TIKVA, ISRAEL /s/ Ronnen Armon 18 Mar 2026 0001970877

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CLBT Ordinary shares, par value NIS 0.00001 ("Ordinary Shares") 277,844 18 Mar 2026 Direct F1, F2, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CLBT Stock options 18 Mar 2026 Ordinary Shares 60,606 $6.60 Direct F6
holding CLBT Stock options 18 Mar 2026 Ordinary Shares 80,808 $4.95 Direct F7
holding CLBT Stock options 18 Mar 2026 Ordinary Shares 43,440 $11.51 Direct F8
holding CLBT Stock options 18 Mar 2026 Ordinary Shares 43,440 $11.51 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 29,320 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on February 14, 2023, of which 7,330 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.
F2 Includes 24,030 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,670 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.
F3 Includes 27,768 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,136 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029.
F4 Includes 5,341 Ordinary Shares that are represented by performance share units ("PSUs") that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028. Each PSU represents a contingent right to receive one Ordinary Share of the Issuer upon vesting and settlement.
F5 Includes 5,341 Ordinary Shares that are represented by PSUs that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028.
F6 These stock options are fully vested and exercisable.
F7 Of these stock options, 60,608 are fully vested and exercisable and 5,050 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027.
F8 Of these stock options, 19,005 are fully vested and exercisable and 2,715 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.
F9 Of these stock options, 15,204 are fully vested and exercisable and 2,172 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029.

Remarks:

Chief Products & Technologies Officer